Novartis reports positive topline results of twice-yearly Leqvio in Phase III V-MONO study

BASEL (dpa-AFX) – Novartis (NVS) reported positive topline results with twice-yearly Leqvio in the Phase III V-MONO study, which met its primary endpoints. In the study, Leqvio monotherapy achieved clinically meaningful and statistically significant reductions in LDL cholesterol versus both placebo and ezetimibe in patients at low to moderate risk of developing atherosclerotic cardiovascular disease and who were not receiving lipid-lowering therapy.

Shreeram Aradhye, President, Development and Chief Medical Officer at Novartis, said: “This study adds to the growing evidence base for Leqvio across the full spectrum of ASCVD as we aim to help more patients in need.”

Novartis plans to present the study results at an upcoming medical meeting and share them with regulatory authorities, including the FDA.

Visit rttnews.com for more health news.

Related Posts

EADV-Kongress 2024: New Study said that Semaglutid improves the quality of life of patients with high blood pressure

Shivaji statue collapse ‘example of corruption’, says Sharad Pawar

Shined at organic award – The best organic farmer in Europe comes from the Waldviertel region